C2N Diagnostics Revenue and Competitors

Location

#3523

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • C2N Diagnostics's estimated annual revenue is currently $9.5M per year.(i)
  • C2N Diagnostics's estimated revenue per employee is $155,000

Employee Data

  • C2N Diagnostics has 61 Employees.(i)
  • C2N Diagnostics grew their employee count by 65% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$69.9M4518%N/AN/A
#2
$0.9M6-14%N/AN/A
#3
$6.2M40-32%N/AN/A
#4
$0.9M6-14%N/AN/A
#5
$4.2M27-7%N/AN/A
#6
$0.9M6-45%N/AN/A
#7
$4.8M3111%N/AN/A
#8
$3.4M22-15%N/AN/A
#9
$0.4M525%N/AN/A
#10
$4.3M2865%N/AN/A
Add Company

C₂N Diagnostics' vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityAD™ blood test, is a mass spectrometry-based test performed in C₂N's CLIA-certified lab that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer's disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process. PrecivityAD™, which can only be ordered through a health care provider, predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. The PrecivityAD™ blood test also has achieved the CE Mark from the European Union. For more information visit www.C2N.com.

keywords:N/A

N/A

Total Funding

61

Number of Employees

$9.5M

Revenue (est)

65%

Employee Growth %

N/A

Valuation

N/A

Accelerator

C2N Diagnostics News

2022-04-17 - JAMA Network Open Publishes Analysis of Results of Two ...

C 2 N Diagnostics, a leader in advanced brain health diagnostics, announced today that the Journal of the ... SOURCE: C2N Diagnostics.

2022-04-17 - Race of people given Alzheimer's blood tests may affect ...

... C2N Diagnostics — was equally effective at detecting early Alzheimer's disease regardless of the race of the person being tested.

2022-04-17 - Does race affect interpretation of Alzheimer's disease tests?

... disease test they developed in previous work (PrecivityAD, C2N Diagnostics) in 76 pairs of Black and non-Hispanic white participants.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.1M6111%N/A
#2
$13.8M61-2%N/A
#3
$17M6222%N/A
#4
$8.9M6241%N/A
#5
$15.1M62-26%N/A